Breaking News

Compugen Licenses Selexis SUREtechnology Platform

Will leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Compugen Ltd. has licensed the Selexis SUREtechnology Platform for use in generating high-performance research cell banks (RCBs). Compugen will leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics targeting certain cancers, including to support further advancement of COM701.    Compugen’s lead immuno-oncology candidate, COM701, is a humanized hybridoma antibody that binds to PVRIG, a novel B7/CD28-like immune checkpoint target candidate...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters